JNK, P38, ERK, and SGK1 Inhibitors in Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2017 Dec 22

PMID 29267206

Citations 47

Authors

Jonas Cicenas

Egle Zalyte

Arnas Rimkus

Dalius Dapkus

Remigijus Noreika

Sigitas Urbonavicius

Affiliations

Soon will be listed here.

Abstract

Mitogen-activated protein kinases (MAP kinases) are a family of kinases that regulates a range of biological processes implicated in the response to growth factors like latelet-derived growth factor (PDGF), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), and stress, such as ultraviolet irradiation, heat shock, and osmotic shock. The MAP kinase family consists of four major subfamilies of related proteins (extracellular regulated kinases 1/2 (ERK1/2), c-Jun N-terminal kinase (JNK), p38, and extracellular regulated kinase 5 (ERK5)) and regulates numerous cellular activities, such as apoptosis, gene expression, mitosis, differentiation, and immune responses. The deregulation of these kinases is shown to be involved in human diseases, such as cancer, immune diseases, inflammation, and neurodegenerative disorders. The awareness of the therapeutic potential of the inhibition of MAP kinases led to a thorough search for small-molecule inhibitors. Here, we discuss some of the most well-known MAP kinase inhibitors and their use in cancer research.

Citing Articles

Transmembrane Amino Acid Transporters in Shaping the Metabolic Profile of Breast Cancer Cell Lines: The Focus on Molecular Biological Subtype.

Dyachenko E, Belskaya L Curr Issues Mol Biol. 2025; 47(1).

PMID: 39852119 PMC: 11763447. DOI: 10.3390/cimb47010004.

Targeting the p90RSK/MDM2/p53 Pathway Is Effective in Blocking Tumors with Oncogenic Up-Regulation of the MAPK Pathway Such as Melanoma and Lung Cancer.

Maietta I, Viscusi E, Laudati S, Iannaci G, DAntonio A, Melillo R Cells. 2024; 13(18.

PMID: 39329730 PMC: 11430938. DOI: 10.3390/cells13181546.

LncRNA MEG3 Inhibits the Epithelial-mesenchymal Transition of Bladder Cancer Cells through the Snail/E-cadherin Axis.

Wang L, Wang P, Liu B, Zhang H, Wei C, Xiong M Curr Med Sci. 2024; 44(4):726-734.

PMID: 38990449 DOI: 10.1007/s11596-024-2895-x.

CDK Inhibitors and FDA: Approved and Orphan.

Cicenas J, Simkus J Cancers (Basel). 2024; 16(8).

PMID: 38672637 PMC: 11049492. DOI: 10.3390/cancers16081555.

Mechanism of action and therapeutic targeting of CD30 molecule in lymphomas.

Li Z, Guo W, Bai O Front Oncol. 2024; 13:1301437.

PMID: 38188299 PMC: 10767573. DOI: 10.3389/fonc.2023.1301437.

References

Rovida E, Maira G, Tusa I, Cannito S, Paternostro C, Navari N . The mitogen-activated protein kinase ERK5 regulates the development and growth of hepatocellular carcinoma. Gut. 2014; 64(9):1454-65. DOI: 10.1136/gutjnl-2014-306761. View

Giafis N, Katsoulidis E, Sassano A, Tallman M, Higgins L, Nebreda A . Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses. Cancer Res. 2006; 66(13):6763-71. DOI: 10.1158/0008-5472.CAN-05-3699. View

Zheng K, Iqbal S, Hernandez P, Park H, LoGrasso P, Feng Y . Design and synthesis of highly potent and isoform selective JNK3 inhibitors: SAR studies on aminopyrazole derivatives. J Med Chem. 2014; 57(23):10013-30. PMC: 4266361. DOI: 10.1021/jm501256y. View

Wang W, Shi L, Xie Y, Ma C, Li W, Su X . SP600125, a new JNK inhibitor, protects dopaminergic neurons in the MPTP model of Parkinson's disease. Neurosci Res. 2004; 48(2):195-202. DOI: 10.1016/j.neures.2003.10.012. View

Li J, Huang J, Xing B, Ren K, Li M, Wei D . SP600125, a JNK inhibitor, suppresses growth of JNK-inactive glioblastoma cells through cell-cycle G2/M phase arrest. Pharmazie. 2012; 67(11):942-6. View

Cicenas J, Tamosaitis L, Kvederaviciute K, Tarvydas R, Staniute G, Kalyan K . KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma. Med Oncol. 2017; 34(2):26. DOI: 10.1007/s12032-016-0879-9. View

Derijard B, Hibi M, Wu I, Barrett T, Su B, Deng T . JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell. 1994; 76(6):1025-37. DOI: 10.1016/0092-8674(94)90380-8. View

Uehara T, Bennett B, Sakata S, Satoh Y, Bilter G, Westwick J . JNK mediates hepatic ischemia reperfusion injury. J Hepatol. 2005; 42(6):850-9. DOI: 10.1016/j.jhep.2005.01.030. View

Minutoli L, Altavilla D, Marini H, Passaniti M, Bitto A, Seminara P . Protective effects of SP600125 a new inhibitor of c-jun N-terminal kinase (JNK) and extracellular-regulated kinase (ERK1/2) in an experimental model of cerulein-induced pancreatitis. Life Sci. 2004; 75(24):2853-66. DOI: 10.1016/j.lfs.2004.03.040. View

10.

Seiwert S, Stines Nahreini T, Aigner S, Ahn N, Uhlenbeck O . RNA aptamers as pathway-specific MAP kinase inhibitors. Chem Biol. 2000; 7(11):833-43. DOI: 10.1016/s1074-5521(00)00032-6. View

11.

Kim J, Chae M, Choi A, Kim H, Yoon S . SP600125 overcomes antimitotic drug-resistance in cancer cells by increasing apoptosis with independence of P-gp inhibition. Eur J Pharmacol. 2013; 723:141-7. DOI: 10.1016/j.ejphar.2013.11.026. View

12.

Cerbone A, Toaldo C, Pizzimenti S, Pettazzoni P, Dianzani C, Minelli R . AS601245, an Anti-Inflammatory JNK Inhibitor, and Clofibrate Have a Synergistic Effect in Inducing Cell Responses and in Affecting the Gene Expression Profile in CaCo-2 Colon Cancer Cells. PPAR Res. 2012; 2012:269751. PMC: 3349252. DOI: 10.1155/2012/269751. View

13.

Honda M, Kanno T, Fujita Y, Gotoh A, Nakano T, Nishizaki T . Mesothelioma cell proliferation through autocrine activation of PDGF-ββ receptor. Cell Physiol Biochem. 2012; 29(5-6):667-74. DOI: 10.1159/000176386. View

14.

Kvederaviciute K, Meskinyte I, Meskinyte-Kausiliene E, Skeberdyte A, Cicenas J . KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer. Cancers (Basel). 2017; 9(5). PMC: 5447952. DOI: 10.3390/cancers9050042. View

15.

Gaillard P, Jeanclaude-Etter I, Ardissone V, Arkinstall S, Cambet Y, Camps M . Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase. J Med Chem. 2005; 48(14):4596-607. DOI: 10.1021/jm0310986. View

16.

Nguyen A, Stebbins E, Henson M, OYoung G, Choi S, Quon D . Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation. Exp Cell Res. 2006; 312(10):1909-23. DOI: 10.1016/j.yexcr.2006.02.026. View

17.

Cicenas J, Kalyan K, Sorokinas A, Jatulyte A, Valiunas D, Kaupinis A . Highlights of the Latest Advances in Research on CDK Inhibitors. Cancers (Basel). 2014; 6(4):2224-42. PMC: 4276963. DOI: 10.3390/cancers6042224. View

18.

Schreiber S, Feagan B, DHaens G, Colombel J, Geboes K, Yurcov M . Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006; 4(3):325-34. DOI: 10.1016/j.cgh.2005.11.013. View

19.

Selness S, Devraj R, Devadas B, Walker J, Boehm T, Durley R . Discovery of PH-797804, a highly selective and potent inhibitor of p38 MAP kinase. Bioorg Med Chem Lett. 2011; 21(13):4066-71. DOI: 10.1016/j.bmcl.2011.04.121. View

20.

Vanderkerken K, Medicherla S, Coulton L, De Raeve H, Willems A, Lawson M . Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma. Cancer Res. 2007; 67(10):4572-7. DOI: 10.1158/0008-5472.CAN-06-4361. View